People: Acorda Therapeutics, Inc. (ACOR.O)

ACOR.O on Consolidated Issue listed on NASDAQ Global Market

29.99USD
9 Feb 2010
Price Change (% chg)

$0.07 (+0.23%)
Prev Close
$29.99
Open
--
Day's High
$30.43
Day's Low
$29.94
Volume
954,133
Avg. Vol
1,554,357
52-wk High
$31.78
52-wk Low
$15.52

view people for:

Summary

Name Age Since Current Position
Cohen, Ron 53 President,Chief Executive Officer, Director
Lawrence, David 51 2005 Chief Financial Officer
Wasman, Jane 52 2004 Executive Vice President, General Counsel, Secretary
Sabella, Lauren 47 2010 Executive Vice President - Commercial Development
Blight, Andrew 58 2004 Chief Scientific Officer
Wessel, Thomas 53 2008 Chief Medical Officer
Panem, Sandra 62 1998 Director
Randall, Lorin 66 2006 Director
Rauscher, Steven 55 2005 Director
Young, Wise 59 1995 Director
Greene, Barry 45 2007 Director
Smith, Ian 43 2007 Director
Kelley, John 55 2008 Director
» Insider Trading

Biographies

Name Description
Cohen, Ron Mr. Ron Cohen, M.D., is President, Chief Executive Officer, Director of Acorda Therapeutics Inc. He is President and Chief Executive Officer since he founded Acorda Therapeutics in 1995. Dr. Cohen previously was a principal in the startup of Advanced Tissue Sciences, Inc., a biotechnology company engaged in the growth of human organ tissues for transplantation uses. Dr. Cohen received his B.A. degree with honors in Psychology from Princeton University, and his M.D. from the Columbia College of Physicians & Surgeons. He completed a residency in Internal Medicine at the University of Virginia Medical Center, and is Board Certified in Internal Medicine. Dr. Cohen previously was Chairman Emeritus of the board of the New York Biotechnology Association. He also serves as a member of the Health Care Governing Body and the Emerging Company Section of the board of the Biotechnology Industry Organization (BIO), and as a member of the Columbia-Presbyterian Health Sciences Advisory Council. Dr. Cohen is a recipient of the Ernst & Young Entrepreneur of the Year Award for the New York Metropolitan Region, and an inductee into the National Spinal Cord Injury Association's "Spinal Cord Injury Hall of Fame."
Lawrence, David Mr. David Lawrence, M.B.A., is Chief Financial Officer of Acorda Therapeutics Inc. He previously served as Vice President, Finance from January 2001 through 2004, and Director, Finance from 1999 to 2001. From 1991 to 1999, Mr. Lawrence held several positions for Tel-Air Communications, Inc. including Vice President and Controller. Prior to Tel-Air, he held financial management positions of Controller and Finance Manager for Southwestern Bell and Metromedia Telecommunications, respectively. Mr. Lawrence received his undergraduate degree in Accounting from Roger Williams College, and an M.B.A in Finance from Iona College. Mr. Lawrence is a founding member and currently serves on the board of directors as Treasurer of The Brian Ahearn Children's Fund.
Wasman, Jane Ms. Jane Wasman, J.D., is Executive Vice President, General Counsel and Corporate Secretary of Acorda Therapeutics Inc since May 2004. From 1995 to 2004, Ms. Wasman held various leadership positions at Schering-Plough Corporation, including Staff Vice President and Associate General Counsel responsible for legal support for U.S. Pharmaceuticals operations, including sales, marketing and compliance; FDA regulatory matters; global research and development; and corporate licensing and business development. She served as Staff Vice President, International in 2001 and as Staff Vice President, European Operations—Legal from 1998 to 2000. Previously, Ms. Wasman specialized in litigation at Fried, Frank, Harris, Shriver & Jacobson. She also served as Associate General Counsel to the U.S. Senate Committee on Veteran's Affairs. Ms. Wasman graduated Magna Cum Laude and Phi Beta Kappa from Princeton University and earned her J.D. from Harvard Law School. Ms. Wasman is a member of the board of Directors of the New York Biotechnology Association.
Sabella, Lauren Ms. Lauren Sabella is the Executive Vice President - Commercial Development of Acorda Therapeutics, Inc. She was appointed as Executive Officer of the company effective January 2010. Before joining Acorda, Ms. Sabella was the Founder and Principal of Tugboat Consulting Group, an independent consulting practice assisting companies in the commercialization process. Ms. Sabella also served as Corporate Officer and VP of Commercial Development at Altus Pharmaceuticals, with responsibility for all aspects of commercialization. Prior to joining Altus, Ms. Sabella was employed by Boehringer Ingelheim Pharmaceuticals for 18 years in positions of increasing responsibility. In her last role, she served as VP of Sales, Eastern Zone, where she led the successful sales launch of Spiriva and ran both Primary Care and Specialty Divisions, including Neurology, Urology and Cardio/Pulmonary. Prior to this role, she had over ten years of marketing experience where she led several brand launches including Mobic, an NSAID which became a $1 billion dollar brand. Ms. Sabella holds a B.B.A. from Hofstra University.
Blight, Andrew Mr. Andrew R. Blight, Ph.D., has been Chief Scientific Officer since January 2004 and previously served as Executive Vice President, Research and Development from 2000 to 2004, and Vice President, Research and Development, from 1998 to 2000. Prior to joining Acorda, Dr. Blight spent approximately six years as Professor and Director of the Neurosurgery Research Laboratory at the University of North Carolina at Chapel Hill. Dr. Blight held prior academic positions at Purdue University and New York University. Dr. Blight is a leader in SCI pathophysiology research and has made several important contributions to the field, particularly on the role of demyelination in SCI. He also pioneered the therapeutic application of 4-AP in SCI animal models and in human clinical trials. Dr. Blight is a member of the editorial board of the Journal of Neurotrauma and has served as a member of the NIH NSDA review committee. He was previously Secretary, Treasurer and Vice President of the National Neurotrauma Society. Dr. Blight received his B.S. in Zoology and his Ph.D. in Zoology/Neurobiology from the University of Bristol, U.K.
Wessel, Thomas Dr. Thomas C. Wessel, M.D., Ph.D., is Chief Medical Officer of Acorda Therapeutics, Inc. In this role, Dr. Wessel is having responsibility for the Company's Clinical Development and Operations, Regulatory Affairs, Biostatistics, Data Management and Drug Safety functions. Previously, Dr. Wessel was Senior Vice President of Clinical Research at Sepracor, Inc., where he led the central nervous system (CNS) and respiratory medicine development teams, including clinical research and operations, clinical pharmacology, drug safety and medical writing. During this time, he served as the medical director for the Lunesta(R) (eszopiclone) development program and helped establish partnerships for this product in the EU with GlaxoSmithKline and in Japan with Eisai. He also participated in numerous business development activities at Sepracor, eventually leads to in-licensing eslicarbazepine, an antiepileptic agent with potential uses in epilepsy, bipolar disease and neuropathic pain. Before joining Sepracor in 2002, Dr. Wessel worked on several CNS projects at Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson), including Global Medical Leader for lubeluzole, a neuroprotective agent tested in acute ischemic stroke and traumatic brain injury. His work on that product included managing clinical trials in Europe and interacting with regulatory agencies in several EU member states. He also headed the New Drug Application (NDA) submission team for Razadyne(R) (galantamine) which was approved by the FDA for the treatment of mild-moderate Alzheimer's disease in 2001. Dr. Wessel received his M.D. from the University of Munich School of Medicine and completed his Ph.D. in experimental neurobiology at the Max-Planck-Institute for Psychiatry in Martinsried, Germany. He completed his residency in neurology at New York Hospital and Memorial Sloan-Kettering Cancer Center (Cornell University Medical Center) and remained on the faculty in the Department of Neurology and Neuroscience until 1995.
Panem, Sandra Ms. Sandra Panem, Ph.D., is Directors of Acorda Therapeutics Inc since 1998. She is currently a partner at Cross Atlantic Partners, which she joined in 2000. From 1994 to 1999, Dr. Panem was President of Vector Fund Management, the then asset management affiliate of Vector Securities International. Prior thereto, Dr. Panem served as Vice President and Portfolio Manager for the Oppenheimer Global BioTech Fund, a mutual fund that invested in public and private biotechnology companies. Previously, she was Vice President at Salomon Brothers Venture Capital, a fund focused on early and later-stage life sciences and technology investments. Dr. Panem was also a Science and Public Policy Fellow in economic studies at the Brookings Institution, and an Assistant Professor of Pathology at the University of Chicago. She received a B.S. in biochemistry and Ph.D. in microbiology from the University of Chicago. Dr. Panem currently serves on the boards of Directors of Labcyte, Inc., GenomeQuest, Inc., and MDx Medical, Inc.
Randall, Lorin Mr. Lorin J. Randall is Directors of Acorda Therapeutics Inc since January 2006. Mr. Randall is an independent financial consultant and previously was Senior Vice President and Chief Financial Officer of Eximias Pharmaceutical Corporation, a development-stage drug development company, from 2004 to 2006. From 2002 to 2004, Mr. Randall served as Senior Vice President and Chief Financial Officer of i-STAT Corporation, a publicly-traded manufacturer of medical diagnostic devices that was acquired by Abbott Laboratories in 2004. From 1995 to 2001, Mr. Randall was Vice President and Chief Financial Officer of CFM Technologies, Inc. a publicly-traded manufacturer of semiconductor manufacturing equipment. Mr. Randall previously served on the board of directors of Quad Systems Corporation, a publicly-traded manufacturer of electronics manufacturing equipment, where he served as Chairman of the Audit Committee. Mr. Randall currently serves on the boards of directors of Point 5 Technologies, Inc. and Rapid Micro Biosystems, Inc. Mr. Randall received a B.S. in accounting from The Pennsylvania State University and an M.B.A. from Northeastern University.
Rauscher, Steven Mr. Steven M. Rauscher is Director of Acorda Therapeutics Inc since 2005. He is President and CEO of Oscient Pharmaceuticals Corporation, a commercial stage biopharmaceutical company. He joined Oscient in 2000 having served as a member of the Board of Directors since 1993. Previously, Mr. Rauscher was CEO of AmericasDoctor, a company providing clinical research services to the pharmaceutical industry. Prior to AmericasDoctor, he held a number of leadership positions at Abbott Laboratories, including Vice President of Corporate Licensing, Vice President of Business Development, International Division and Vice President of Sales, U.S. Pharmaceuticals. Mr. Rauscher received a B.S. from Indiana University and an M.B.A. from the University of Chicago.
Young, Wise Mr. Wise Young, Ph.D., M.D., is Directors of Acorda Therapeutics Inc. He is scientific advisory board since the founding of the company in 1995. Dr. Young has been at Rutgers University since 1997, where he serves as the Richard H. Shindell Chair in Neuroscience and Founding Director of the W.M. Keck Center for Neuroscience. Dr. Young is one of the preeminent scientists in the fields of spinal cord injury and neurotrauma, SCI animal models, and the pharmacological therapy of SCI. He was the Principal Investigator for the Multicenter Animal Spinal Cord Injury Study funded by the National Institutes of Health; founded the Journal of Neurotrauma and has served on the editorial boards of many other journals including Neurosurgery and Stroke. Dr. Young received the Wakeman Award for Research in Neurosciences, and a Jacob Javits Neuroscience Award from the National Institute of Neurological Disorder and Stroke. From 2000-2005, Dr. Young was a member of The Council of the National Institute of Child Health and Disorders (NICHD) and he served on many NIH study sections and advisory boards from 1980-2000. He is a member of the Working Group of the California Institute of Regenerative Medicine (CIRM) that is responsible for scientific review of stem cell research funded by California. Since 2006, Dr. Young has served as Distinguished Visiting Professor at Hong Kong University, and he is organizing spinal cord injury clinics in China. Dr. Young received a B.A. in biology and chemistry from Reed College, a Ph.D. in physiology and biophysics from the University of Iowa and an M.D. from Stanford University.
Greene, Barry Mr. Barry Greene is Directors of Acorda Therapeutics Inc since January 2007. Mr. Greene currently serves as Chief Operating Officer of Alnylam Pharmaceuticals, Inc. Mr. Greene joined Alnylam in October 2003, bringing over 15 years of experience in the healthcare industry and in consulting. Prior to Alnylam, he was General Manager of Oncology at Millennium Pharmaceuticals, Inc., where he led the company’s global strategy and execution for its oncology business including strategic business direction and execution, culminating in the successful approval and launch of VELCADE (bortezomib) in mid-2003. Prior to joining Millennium in February 2001, Mr. Greene served as Executive Vice President and Chief Business Officer for Mediconsult.com. Prior to Mediconsult.com, Mr. Greene’s past experience included being Vice President of Marketing and Customer Services for AstraZeneca (formerly AstraMerck); Vice President Strategic Integration with responsibility for the AstraZeneca North American post-merger integration; and partner of Andersen Consulting, responsible for the pharmaceutical/biotechnology marketing and sales practice. Mr. Greene received his B.S. in Industrial Engineering from the University of Pittsburgh and serves as a Senior Scholar at Duke University, Fuqua School of Business.
Smith, Ian Mr. Ian Smith is Director of Acorda Therapeutics Inc since February 2007. Mr. Smith currently serves as Executive Vice President and Chief Financial Officer of Vertex Pharmaceuticals, Inc., a position he has held since February 2006. From November 2003 to February 2006, he was Senior Vice President and Chief Financial Officer, and from October 2001 to November 2003, he served as Vice President and Chief Financial Officer, at Vertex. From 1999 to 2001, Mr. Smith served as a partner in the Life Science and Technology Practice Group of Ernst & Young LLP. Mr. Smith initially joined Ernst & Young’s U.K. firm in 1987, and then joined its Boston office in 1995. Mr. Smith currently is a member of the boards of directors of Predix Pharmaceuticals, Inc. and TolerRx Inc. Mr. Smith holds a B.A. in accounting and finance from Manchester Metropolitan University, U.K., is a member of the American Institute of Certified Public Accountants and is a Chartered Accountant of England and Wales.
Kelley, John Mr. John P. Kelley is Directors of Acorda Therapeutics, Inc. Mr. Kelley has been the President and Chief Operating Officer of The Medicines Company, a developer of acute care hospital pharmaceutical products, since December 2004. Prior to joining The Medicines Company, Mr. Kelley held several senior management positions at Aventis Pharmaceuticals, Inc., most recently as Senior Vice President Global Marketing and Medical, where he was responsible for worldwide brand management of its core strategic brands and also managed strategic alliances with its partner companies. Previously, he served there as Senior Vice President, Strategic Risk Officer and Vice President, Head of Strategic Development, the strategic planning process of the pharmaceutical division of Aventis as well as merger and acquisition activity. Prior to the formation of Aventis, he served as Vice President Commercial Director, U.S. and as Vice President of Marketing at Hoechst Marion Roussel, Inc. Mr. Kelley received a B.A. from Wilkes University and an M.B.A. from Rockhurst University.

Basic Compensation

Name Fiscal Year Total
Cohen, Ron 1,577,880
Lawrence, David 961,860
Wasman, Jane 1,046,810
Sabella, Lauren --
Blight, Andrew 1,085,100
Wessel, Thomas --
Panem, Sandra --
Randall, Lorin --
Rauscher, Steven --
Young, Wise --
Greene, Barry --
Smith, Ian --
Kelley, John --
As Of 30 Dec 2008

Options Compensation

Name Options Value
Cohen, Ron 835,605 9,721,775
Lawrence, David 143,889 1,622,787
Wasman, Jane 48,269 262,753
Sabella, Lauren 0 0
Blight, Andrew 201,947 2,635,837
Wessel, Thomas 0 0
Panem, Sandra 0 0
Randall, Lorin 0 0
Rauscher, Steven 0 0
Young, Wise 0 0
Greene, Barry 0 0
Smith, Ian 0 0
Kelley, John 0 0

Insider Trading

Name Shares Traded Price
LAWRENCE DAVID 5,000 $8.14
LAWRENCE DAVID 5,000 $30.00
BLIGHT ANDREW 4,534 $30.00
LAWRENCE DAVID 5,000 $28.00
LAWRENCE DAVID 5,000 $8.14
COHEN RON 8,500 $24.51
WASMAN JANE 5,000 $24.50
BLIGHT ANDREW 4,500 $24.51
LAWRENCE DAVID 7,466 $24.51
RANDALL LORIN J 10,000 $23.58
RANDALL LORIN J 10,000 $6.00
BLIGHT ANDREW 16,000 $0.00
WESSEL THOMAS 2,600 $0.00
LAWRENCE DAVID 10,000 $0.00
COHEN RON 25,000 $0.00
WASMAN JANE 15,000 $0.00
PANEM SANDRA 50,000 $23.63
PANEM SANDRA 1,923 $2.60
PANEM SANDRA 1,923 $23.76
COHEN RON 4,000 $15.89
WASMAN JANE 2,500 $15.98
LAWRENCE DAVID 100 $17.09
LAWRENCE DAVID 4,034 $15.99
PANEM SANDRA 25,000 $27.40
COHEN RON 100 $30.34
» Full list on Insider Trading
view people for: